Probiotic composition for use in the treatment of bowel inflammation

Abstract

The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as Inflammatory Bowel Disease, Irritable Bowel Syndrome, or abdominal distension and bloating.

Description

[0001]This application claims the benefit of the U.S. provisional application No. 61 / 299,116, and of the European patent application EP10151998, both filed on 28 Jan. 2010, and which are incorporated herein by reference.[0002]The present invention relates to the fields of medicine, microbiology and nutrition and, particularly, to a novel probiotic composition. Particularly, new strains of Lactobacillus plantarum and Pediococcus acidilactici have been isolated and combined in a formulation useful in the treatment of gastrointestinal diseases, such as bowel inflammation (e.g., inflammatory bowel disease) and irritable bowel syndrome.BACKGROUND OF THE INVENTION[0003]Ulcerative colitis (UC), Pouchitis, and Crohn's Disease are examples of Inflammatory Bowel Diseases (IBD) characterized by chronic inflammation in the intestine. The clinical symptoms are diarrhea, abdominal pain, occasional rectal bleeding, weight loss, tiredness and sometimes fever. Although occurring at any age, IBD is m...

AI Technical Summary

Benefits of technology

The present invention relates to a new composition made up of three strains of Lactobacillus and Pediococcus bacteria that are effective in treating bowel inflammation when used together in a single formulation. This combination of strains helps to reduce inflammation in the bowel and improve overall gut health.

Problems solved by technology

Although occurring at any age, IBD is most common in teenagers and young adults, which consequently may suffer from delayed development and stunted growth.

However, there is currently no medical cure for IBD.

Coloectomy may eliminate UC but reduces life quality and increases the risk of complications.

Diarrhea or abdominal pain appear as side effects of 5-ASA whereas long term use of corticosteroids frequently shows serious side effects including reduction in bone mass, infection, diabetes, muscle wasting and psychiatric disturbances.

However, the resulting immuno-compromised state leaves the patient susceptible to many diseases.

In this regard, various antidepressants have gained popularity although their efficacy in clinical trials has been modest and their clinical utility is limited by untoward side effects.

However, recent concerns about safety have severely limited their use.

Images